Survey on imaging in the management of prostate cancer

Members of the Coalition for Biomedical Imaging and Bioengineering Research (CIBR) are interested in patient perspectives  and experiences in relation to imaging in the diagnosis, work-up, and management of men with or suspected of having prostate cancer. … READ MORE …

Imaging studies for men with recurrent prostate cancer

We had previously reported on a presentation by Calais et al. earlier this year. … READ MORE …

Early data suggest 18F-DCFPyL PET/CT scans can change patient management

A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …

Next-generation imaging in the management of advanced prostate cancer

A new article in the most recent issue of the Journal of Urology provides recommendations for clinicians as to the appropriate, current use of “next-generation” imaging in the treatment of advanced prostate cancer. … READ MORE …

Progenics reports outcome of OSPREY 2301 trial of PyL™

In a media release issued earlier this morning, Progenics Pharmaceuticals has announced the outcome of a Phase II/III trial of their proprietary, PSMA-targeted imaging agent PyL (also known as 18F-DCFPyL) for identification of prostate cancer. … READ MORE …

Trial of new imaging agent nears completion

Early this morning, Progenics Pharmaceuticals announced completion of enrollment of patients in the Phase II/III OSPREY trial of a new PSMA-targeted PET/CT imaging agent for detection of prostate cancer. … READ MORE …

Two leading women talk about the future of treatment of advanced prostate cancer

Nearly 30 years ago, when your sitemaster first attended a prostate cancer meeting (in 1989) related to the upcoming approval of a new drug called flutamide, he doesn’t remember there being a single clinician at the meeting who was female — out of the 150 or so urologists and medical oncologists who had been invited. … READ MORE …